Although the use of sacubitril/valsartan seems to be beneficial in patients with diabetes by potentiating antihyperglycaemic acting of endogenous GLP-1, the use of ARNI in concomitant treatment with GLP-1 long-acting analogues may be harmful in patients with both diabetes and heart failure. Here, GCG is linked to heart failure.